Prostate cancer is the leading cancer among Kenyan men, with an estimated 3,582 men being diagnosed with the disease at some ...
Association of radiomic skeletal muscle features on prostate T1-weighted MRI with major adverse cardiac events in prostate cancer patients. This is an ASCO Meeting Abstract from the 2026 ASCO ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being ...
The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing ...
Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Competitor Analysis: PSMA-Targeted Therapy & Radiodiagnostics" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) ...
Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m. AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results